Important Safety InformationPrescribing Information
arestin logo
Register now
  • Important Safety Information
  • Prescribing Information
  • Register now

Empower your team with our interactive workshops

doctors talking in clinic

Our workshops will increase your knowledge about periodontal disease, encourage critical thinking, and support a consistent approach to comprehensive periodontal disease management.

INDICATION

ARESTIN® (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) for reduction of pocket depth in adult periodontitis patients. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

SELECT IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ARESTIN is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines.

Please see additional Important Safety Information below and full Prescribing Information here.

RegisterLearn more in a call

Tailored to you and your team

Each session is customized to fit your team’s needs, with face-to-face or virtual educational opportunities designed for practical, hands-on learning.

Expect real-time discussions, collaborative exercises, and actionable insights you could use immediately.

Tailored to you and your team
Why book a session?

Our workshops may help you

  • ✅ Build a culture of consistency in comprehensive periodontal disease management
  • ✅ Create team alignment
  • ✅ Encourage critical thinking through real-world case studies
Our workshops may help you

A structured approach to learning

Across 4 sessions, you and your team will explore:

  1. Which Patients? How to identify priority periodontal patients
  2. Which Sites? Pinpoint the areas that need targeted attention
  3. What’s Next? Create maintenance plans to support the periodontal patient’s journey
  4. Patient Communication: Bring your patients along the periodontal journey
A structured approach to learning

Ready to book?

Empower your team and elevate your approach to comprehensive periodontal disease management. Book a workshop today and make a measurable difference in your practice.

Alternatively, find out more from our Customer Service team by calling +1 (866) 273-7846.

Indication & Important Safety Information

INDICATION

ARESTIN® (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) for reduction of pocket depth in adult periodontitis patients. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ARESTIN is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines.

WARNINGS AND PRECAUTIONS

  • ARESTIN should not be used in children, pregnant or nursing women as the use of tetracycline drugs during tooth development may cause permanent discoloration of the teeth.
  • Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.
  • Hypersensitivity reactions and hypersensitivity syndrome included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens-Johnson syndrome and erythema multiforme have been reported with oral minocycline.
  • Tetracyclines, including oral minocycline, have been associated with the development of autoimmune syndromes including a lupus-like syndrome manifested by arthralgia, myalgia, rash, and swelling. Sporadic cases of serum sickness-like reaction have presented shortly after oral minocycline use, manifested by fever, rash, arthralgia, lymphadenopathy, and malaise. In symptomatic patients, discontinue use of ARESTIN.
    The use of ARESTIN in an acutely abscessed periodontal pocket or for use in the regeneration of alveolar bone has not been studied.
  • The safety and effectiveness of ARESTIN has not been established in immunocompromised patients or in those with coexistent oral candidiasis. Use with caution if there is a predisposition to oral candidiasis.

ADVERSE REACTIONS
The most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome, and pain.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Click here for full Prescribing Information.

arestin logo

Indication & Important Safety Information

INDICATION

ARESTIN® (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) for reduction of pocket depth in adult periodontitis patients. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ARESTIN is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines.

WARNINGS AND PRECAUTIONS

  • ARESTIN should not be used in children, pregnant or nursing women as the use of tetracycline drugs during tooth development may cause permanent discoloration of the teeth.
  • Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.
  • Hypersensitivity reactions and hypersensitivity syndrome included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens-Johnson syndrome and erythema multiforme have been reported with oral minocycline.
  • Tetracyclines, including oral minocycline, have been associated with the development of autoimmune syndromes including a lupus-like syndrome manifested by arthralgia, myalgia, rash, and swelling. Sporadic cases of serum sickness-like reaction have presented shortly after oral minocycline use, manifested by fever, rash, arthralgia, lymphadenopathy, and malaise. In symptomatic patients, discontinue use of ARESTIN.
    The use of ARESTIN in an acutely abscessed periodontal pocket or for use in the regeneration of alveolar bone has not been studied.
  • The safety and effectiveness of ARESTIN has not been established in immunocompromised patients or in those with coexistent oral candidiasis. Use with caution if there is a predisposition to oral candidiasis.

ADVERSE REACTIONS
The most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome, and pain.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Click here for full Prescribing Information.

ISI Logo
logo-short

We’re here to support you

Contact Us
  • Privacy Policy
  • Legal Notice
  • Cookies Policy
  • Corporate Compliance

orapharma logo

ARESTIN is a trademark of Bausch Health Companies Inc. or its affiliates
©2025 Bausch Health Companies Inc. or its affiliates. All rights reserved. ARE.0109.USA.25